There are no FDA-approved therapies for GPC3, a protein highly expressed by liver cancers. Oricell Therapeutics claims its cell therapy could be best in this class, but it faces competition from companies such as AstraZeneca and Eureka Therapeutics.
The post Oricell Lands $110M to Take Cell Therapy to New Territory in Cancer appeared first on MedCity News.
